Literature DB >> 23462881

The role of epigenetics in Lynch syndrome.

Megan P Hitchins1.   

Abstract

Recognition by Warthin of the familial clustering of colorectal and gynaecological cancers a century ago laid the foundation for the recognition of familial cancer. By tracking afflicted pedigrees, Lynch defined the clinical characteristics and argued for a heritable genetic component to this autosomal dominant cancer susceptibility condition, now termed Lynch syndrome. This was proven in the 1990s, with the discovery of deleterious germline mutations of the mismatch repair genes as its cause. Yet despite the genetic revolution at the turn of the twenty-first century, no pathogenic mutation was identifiable in approximately one-third of cases with suspected Lynch syndrome. In the past decade, the alternative mechanism of constitutional epimutation of the two major mismatch repair genes, MLH1 and MSH2, was identified in a proportion of these outstanding cases. This epigenetic defect, characterized by methylation and transcriptional inactivation of a single genetic allele within normal tissues, predisposes to the development of Lynch-type cancers. MSH2 and some MLH1 epimutations have been linked to genetic alterations within their vicinity and demonstrate dominant inheritance, whilst other MLH1 epimutations are reversible between generations and demonstrate non-Mendelian inheritance. This review charts the discovery of mismatch repair epimutations, their aetiological role in Lynch syndrome and the mechanistic basis for their variable inheritance patterns.

Entities:  

Mesh:

Year:  2013        PMID: 23462881     DOI: 10.1007/s10689-013-9613-3

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  59 in total

1.  Microsatellite instability and the clinicopathological features of sporadic colorectal cancer.

Authors:  R Ward; A Meagher; I Tomlinson; T O'Connor; M Norrie; R Wu; N Hawkins
Journal:  Gut       Date:  2001-06       Impact factor: 23.059

Review 2.  Epigenetic reprogramming in mammals.

Authors:  Hugh D Morgan; Fátima Santos; Kelly Green; Wendy Dean; Wolf Reik
Journal:  Hum Mol Genet       Date:  2005-04-15       Impact factor: 6.150

3.  MLH1 promoter germline-methylation in selected probands of Chinese hereditary non-polyposis colorectal cancer families.

Authors:  Heng-Hua Zhou; Shi-Yan Yan; Xiao-Yan Zhou; Xiang Du; Tai-Ming Zhang; Xu Cai; Yong-Ming Lu; San-Jun Cai; Da-Ren Shi
Journal:  World J Gastroenterol       Date:  2008-12-28       Impact factor: 5.742

4.  Lynch syndrome-associated extracolonic tumors are rare in two extended families with the same EPCAM deletion.

Authors:  Henry T Lynch; Douglas L Riegert-Johnson; Carrie Snyder; Jane F Lynch; Jill Hagenkord; C Richard Boland; Jennifer Rhees; Stephen N Thibodeau; Lisa A Boardman; Janine Davies; Roland P Kuiper; Nicoline Hoogerbrugge; Marjolijn J L Ligtenberg
Journal:  Am J Gastroenterol       Date:  2011-07-19       Impact factor: 10.864

5.  Biallelic MLH1 SNP cDNA expression or constitutional promoter methylation can hide genomic rearrangements causing Lynch syndrome.

Authors:  Monika Morak; Udo Koehler; Hans Konrad Schackert; Verena Steinke; Brigitte Royer-Pokora; Karsten Schulmann; Matthias Kloor; Wilhelm Höchter; Josef Weingart; Cortina Keiling; Trisari Massdorf; Elke Holinski-Feder
Journal:  J Med Genet       Date:  2011-06-28       Impact factor: 6.318

6.  Altered expression of MLH1, MSH2, and MSH6 in predisposition to hereditary nonpolyposis colorectal cancer.

Authors:  Elise Renkonen; Yange Zhang; Hannes Lohi; Reijo Salovaara; Wael M Abdel-Rahman; Mef Nilbert; Kristiina Aittomaki; Heikki J Jarvinen; Jukka-Pekka Mecklin; Annika Lindblom; Paivi Peltomaki
Journal:  J Clin Oncol       Date:  2003-10-01       Impact factor: 44.544

7.  Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability.

Authors:  J M Cunningham; E R Christensen; D J Tester; C Y Kim; P C Roche; L J Burgart; S N Thibodeau
Journal:  Cancer Res       Date:  1998-08-01       Impact factor: 12.701

8.  Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis.

Authors:  H F Vasen; J T Wijnen; F H Menko; J H Kleibeuker; B G Taal; G Griffioen; F M Nagengast; E H Meijers-Heijboer; L Bertario; L Varesco; M L Bisgaard; J Mohr; R Fodde; P M Khan
Journal:  Gastroenterology       Date:  1996-04       Impact factor: 22.682

9.  Methylation of hMLH1 promoter correlates with the gene silencing with a region-specific manner in colorectal cancer.

Authors:  G Deng; E Peng; J Gum; J Terdiman; M Sleisenger; Y S Kim
Journal:  Br J Cancer       Date:  2002-02-12       Impact factor: 7.640

10.  Methylation-specific MLPA (MS-MLPA): simultaneous detection of CpG methylation and copy number changes of up to 40 sequences.

Authors:  Anders O H Nygren; Najim Ameziane; Helena M B Duarte; Raymon N C P Vijzelaar; Quinten Waisfisz; Corine J Hess; Jan P Schouten; Abdellatif Errami
Journal:  Nucleic Acids Res       Date:  2005-08-16       Impact factor: 16.971

View more
  17 in total

Review 1.  Constitutional epimutation as a mechanism for cancer causality and heritability?

Authors:  Megan P Hitchins
Journal:  Nat Rev Cancer       Date:  2015-09-18       Impact factor: 60.716

Review 2.  Finding the needle in a haystack: identification of cases of Lynch syndrome with MLH1 epimutation.

Authors:  Megan P Hitchins
Journal:  Fam Cancer       Date:  2016-07       Impact factor: 2.375

Review 3.  Phenotypic and genotypic heterogeneity of Lynch syndrome: a complex diagnostic challenge.

Authors:  Henry T Lynch; Stephen Lanspa; Trudy Shaw; Murray Joseph Casey; Marc Rendell; Mark Stacey; Theresa Townley; Carrie Snyder; Megan Hitchins; Joan Bailey-Wilson
Journal:  Fam Cancer       Date:  2018-07       Impact factor: 2.375

Review 4.  Genetic predisposition to colorectal cancer: where we stand and future perspectives.

Authors:  Laura Valle
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

Review 5.  The evolution of colorectal cancer genetics-Part 1: from discovery to practice.

Authors:  Andrew T Schlussel; Ronald A Gagliano; Susan Seto-Donlon; Faye Eggerding; Timothy Donlon; Jeffrey Berenberg; Henry T Lynch
Journal:  J Gastrointest Oncol       Date:  2014-10

6.  MLH1 constitutional and somatic methylation in patients with MLH1 negative tumors fulfilling the revised Bethesda criteria.

Authors:  Francesca Crucianelli; Rossella Tricarico; Daniela Turchetti; Greta Gorelli; Francesca Gensini; Roberta Sestini; Laura Giunti; Monica Pedroni; Maurizio Ponz de Leon; Serenella Civitelli; Maurizio Genuardi
Journal:  Epigenetics       Date:  2014-10       Impact factor: 4.528

7.  Recurrent epimutation of SDHC in gastrointestinal stromal tumors.

Authors:  J Keith Killian; Markku Miettinen; Robert L Walker; Yonghong Wang; Yuelin Jack Zhu; Joshua J Waterfall; Natalia Noyes; Parvathy Retnakumar; Zhiming Yang; William I Smith; M Scott Killian; C Christopher Lau; Marbin Pineda; Jennifer Walling; Holly Stevenson; Carly Smith; Zengfeng Wang; Jerzy Lasota; Su Young Kim; Sosipatros A Boikos; Lee J Helman; Paul S Meltzer
Journal:  Sci Transl Med       Date:  2014-12-24       Impact factor: 17.956

Review 8.  Milestones of Lynch syndrome: 1895-2015.

Authors:  Henry T Lynch; Carrie L Snyder; Trudy G Shaw; Christopher D Heinen; Megan P Hitchins
Journal:  Nat Rev Cancer       Date:  2015-02-12       Impact factor: 60.716

Review 9.  Epigenetic Alterations in the Gastrointestinal Tract: Current and Emerging Use for Biomarkers of Cancer.

Authors:  William M Grady; Ming Yu; Sanford D Markowitz
Journal:  Gastroenterology       Date:  2020-12-03       Impact factor: 22.682

10.  A seven-gene CpG-island methylation panel predicts breast cancer progression.

Authors:  Yan Li; Anatoliy A Melnikov; Victor Levenson; Emanuela Guerra; Pasquale Simeone; Saverio Alberti; Youping Deng
Journal:  BMC Cancer       Date:  2015-05-19       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.